Long-term hormone replacement therapy does not cause increased platelet activation

Research output: Contribution to journalArticle

Abstract

Background: Observational studies have shown apparently lower ischemic coronary disease risk in postmenopausal women receiving hormone replacement therapy (HRT). However, several recent studies have shown an increase in ischemic cardiac events when HRT is initiated in postmenopausal women with known coronary artery disease. It is postulated that estrogen may result in increased platelet aggregation. Methods: We evaluated platelet activation, as measured by flow cytometric analysis using P selectin and PAC1 as activation markers, and aggregation, as measured by standard platelet aggregation using platelet-rich plasma, in 27 postmenopausal women (17 HRT, 10 placebo) who were participants in 2 placebo-controlled randomized angiographic trials evaluating the effect of HRT on coronary atherosclerosis or saphenous vein graft disease. All women had received HRT or placebo for >2 years and were on aspirin therapy. The estrogen component was either conjugated equine estrogen or 17β-estradiol. Results: Patients on HRT and those on placebo had comparable degrees of platelet aggregation when measured using various doses of agonists (adenosine diphosphate and epinephrine). There were no significant differences in levels of platelet activation measured by flow cytometry. Conclusion: We conclude that long-term HRT does not appear to cause increased platelet activation and aggregation in women with coronary artery disease. There may be increased platelet activation in the early period after HRT initiation; however, this was not assessed in this study.

Original languageEnglish (US)
Pages (from-to)434-438
Number of pages5
JournalAmerican Heart Journal
Volume150
Issue number3
DOIs
StatePublished - Sep 2005

Fingerprint

Hormone Replacement Therapy
Platelet Activation
Platelet Aggregation
Placebos
Coronary Artery Disease
Estrogens
Conjugated (USP) Estrogens
Platelet-Rich Plasma
P-Selectin
Saphenous Vein
Adenosine Diphosphate
Epinephrine
Aspirin
Observational Studies
Coronary Disease
Estradiol
Coronary Vessels
Flow Cytometry
Randomized Controlled Trials
Transplants

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{3555cac8ca38468b94593a3737c66f34,
title = "Long-term hormone replacement therapy does not cause increased platelet activation",
abstract = "Background: Observational studies have shown apparently lower ischemic coronary disease risk in postmenopausal women receiving hormone replacement therapy (HRT). However, several recent studies have shown an increase in ischemic cardiac events when HRT is initiated in postmenopausal women with known coronary artery disease. It is postulated that estrogen may result in increased platelet aggregation. Methods: We evaluated platelet activation, as measured by flow cytometric analysis using P selectin and PAC1 as activation markers, and aggregation, as measured by standard platelet aggregation using platelet-rich plasma, in 27 postmenopausal women (17 HRT, 10 placebo) who were participants in 2 placebo-controlled randomized angiographic trials evaluating the effect of HRT on coronary atherosclerosis or saphenous vein graft disease. All women had received HRT or placebo for >2 years and were on aspirin therapy. The estrogen component was either conjugated equine estrogen or 17β-estradiol. Results: Patients on HRT and those on placebo had comparable degrees of platelet aggregation when measured using various doses of agonists (adenosine diphosphate and epinephrine). There were no significant differences in levels of platelet activation measured by flow cytometry. Conclusion: We conclude that long-term HRT does not appear to cause increased platelet activation and aggregation in women with coronary artery disease. There may be increased platelet activation in the early period after HRT initiation; however, this was not assessed in this study.",
author = "Marlene Williams and Dhananjay Vaidya and Kickler, {Thomas Stephen} and Pamela Ouyang",
year = "2005",
month = "9",
doi = "10.1016/j.ahj.2004.10.028",
language = "English (US)",
volume = "150",
pages = "434--438",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term hormone replacement therapy does not cause increased platelet activation

AU - Williams, Marlene

AU - Vaidya, Dhananjay

AU - Kickler, Thomas Stephen

AU - Ouyang, Pamela

PY - 2005/9

Y1 - 2005/9

N2 - Background: Observational studies have shown apparently lower ischemic coronary disease risk in postmenopausal women receiving hormone replacement therapy (HRT). However, several recent studies have shown an increase in ischemic cardiac events when HRT is initiated in postmenopausal women with known coronary artery disease. It is postulated that estrogen may result in increased platelet aggregation. Methods: We evaluated platelet activation, as measured by flow cytometric analysis using P selectin and PAC1 as activation markers, and aggregation, as measured by standard platelet aggregation using platelet-rich plasma, in 27 postmenopausal women (17 HRT, 10 placebo) who were participants in 2 placebo-controlled randomized angiographic trials evaluating the effect of HRT on coronary atherosclerosis or saphenous vein graft disease. All women had received HRT or placebo for >2 years and were on aspirin therapy. The estrogen component was either conjugated equine estrogen or 17β-estradiol. Results: Patients on HRT and those on placebo had comparable degrees of platelet aggregation when measured using various doses of agonists (adenosine diphosphate and epinephrine). There were no significant differences in levels of platelet activation measured by flow cytometry. Conclusion: We conclude that long-term HRT does not appear to cause increased platelet activation and aggregation in women with coronary artery disease. There may be increased platelet activation in the early period after HRT initiation; however, this was not assessed in this study.

AB - Background: Observational studies have shown apparently lower ischemic coronary disease risk in postmenopausal women receiving hormone replacement therapy (HRT). However, several recent studies have shown an increase in ischemic cardiac events when HRT is initiated in postmenopausal women with known coronary artery disease. It is postulated that estrogen may result in increased platelet aggregation. Methods: We evaluated platelet activation, as measured by flow cytometric analysis using P selectin and PAC1 as activation markers, and aggregation, as measured by standard platelet aggregation using platelet-rich plasma, in 27 postmenopausal women (17 HRT, 10 placebo) who were participants in 2 placebo-controlled randomized angiographic trials evaluating the effect of HRT on coronary atherosclerosis or saphenous vein graft disease. All women had received HRT or placebo for >2 years and were on aspirin therapy. The estrogen component was either conjugated equine estrogen or 17β-estradiol. Results: Patients on HRT and those on placebo had comparable degrees of platelet aggregation when measured using various doses of agonists (adenosine diphosphate and epinephrine). There were no significant differences in levels of platelet activation measured by flow cytometry. Conclusion: We conclude that long-term HRT does not appear to cause increased platelet activation and aggregation in women with coronary artery disease. There may be increased platelet activation in the early period after HRT initiation; however, this was not assessed in this study.

UR - http://www.scopus.com/inward/record.url?scp=24944490908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944490908&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.10.028

DO - 10.1016/j.ahj.2004.10.028

M3 - Article

C2 - 16169320

AN - SCOPUS:24944490908

VL - 150

SP - 434

EP - 438

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -